Comparative Pharmacology
Head-to-head clinical analysis: MOXAM versus MOXATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXAM versus MOXATAG.
MOXAM vs MOXATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Amoxicillin (extended-release) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors, leading to cell lysis and death via activation of autolytic enzymes.
400 mg orally every 24 hours for 7-14 days.
775 mg orally once daily for 7 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; prolonged in renal impairment (up to 20 hours with CrCl <30 mL/min).
The terminal elimination half-life is 1.0–1.5 hours in healthy adults; however, with the extended-release formulation (Moxatag), the effective half-life is prolonged to support once-daily dosing.
Renal: ~70% unchanged; biliary/fecal: ~20% as unchanged drug and metabolites; minor metabolism via glucuronidation.
Approximately 60% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 20% is excreted in feces via biliary elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic